Mobile Site ›
Print Friendly View

Test ID: 17BFP    
Fluticasone 17-Beta-Carboxylic Acid, Urine

Useful For Suggests clinical disorders or settings where the test may be helpful

Assessing compliance (recent exposure) to fluticasone propionate therapy

 

An aid in the evaluation of secondary adrenal insufficiency

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Inhaled corticosteroids are the single most effective therapy for adult patients with asthma. Even low doses of inhaled corticosteroids have been shown to reduce mortality related to asthma. The September 2007 issue of Pediatrics reported that "Verification of [asthma] treatment adherence by objective measures remains necessary."(1) In this pediatric asthma adherence study, the 104 asthmatic children and their parents grossly overestimated their medication adherence. Over 1 of 3 responses reported full compliance to medications when no medications had been taken. Over 46% of individuals exaggerated their adherence by at least 25%. The authors concluded that "Under the best of conditions in this study, accuracy of self-report was insufficient to provide a stand-alone measure of adherence."(1,2)

 

Fluticasone propionate (FP) is an inhaled corticosteroid with anti-inflammatory and immunosuppressive properties commonly used for the treatment of asthma, airway inflammation, and allergic rhinitis. FP is typically well tolerated and has a low risk for adverse systemic effects when utilized at recommended therapeutic doses. However, noncompliance with recommended FP therapy may result in poorly controlled asthma or misinterpretation of the patient's therapeutic responsiveness. Patients with excessive exposure to FP may present with clinical features of Cushing syndrome, but with evidence of hypothalamus-pituitary-adrenal axis suppression, including suppressed cortisol levels. Conversely, a patient not administering the drug as recommended may have their therapeutic responsiveness interpreted, in error by the patient or clinician, as steroid-resistance.

 

FP has low oral bioavailability and high hepatic first-pass metabolism, which results in low plasma FP concentrations; any systemic levels are believed to occur through adsorption from the lungs. Native FP absorbed by the gastrointestinal tract (<1% total FP) is rapidly metabolized by cytochrome P450 isoform 3A4 to yield fluticasone 17-beta-carboxylic acid, its primary metabolic product.(3) Fluticasone 17-beta-carboxylic acid is pharmacologically inactive and has increased water solubility such that it is excreted in urine. Accordingly, fluticasone 17-beta-carboxylic acid is detected in urine in individuals recently exposed to inhaled FP therapy. Fluticasone 17-beta-carboxylic acid may be detected in urine as early as 16 to 24 hours following a patient's first administration of low dose (220 mcg) FP therapy. The window of detection for fluticasone 17-beta-carboxylic acid is 6 days following cessation of FP therapy.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Negative

Cutoff concentration: 10 pg/mL

 

Values for normal patients not taking fluticasone propionate should be less than the cutoff concentration (detection limit).

Interpretation Provides information to assist in interpretation of the test results

Elevated fluticasone 17-beta-carboxylic acid indicates recent exposure to fluticasone propionate (FP).

 

Fluticasone 17-beta carboxylic acid concentration <10 pg/mL indicates that the patient may not have administered inhaled FP therapy within the preceding 6 days. Validated concerns about suboptimal patient adherence to asthma controller medications should lead to patient and provider interactions to address potential compliance issues.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Patients using fluticasone propionate (FP) therapy concurrently with a CYP3A4 inhibitor (eg, indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, or telithromycin) may be at increased risk of adrenal insufficiency because of reduced FP metabolism to fluticasone 17-beta carboxylic acid, with increased levels of the corticosteroid FP and suppression of adrenal cortisol production.(4) In this situation, urine fluticasone 17-beta carboxylic acid concentrations may be below the limit of quantitation.  

 

The Endocrine Laboratory should be notified if a urine specimen from a patient receiving fluorometholone therapy is to be analyzed for fluticasone 17-beta-carboxylic acid because fluorometholone is used as an internal standard in this method. If the laboratory is not notified and a significant amount of fluorometholone is present in the urine, a false-negative result may be reported.

Clinical Reference Provides recommendations for further in-depth reading of a clinical nature

1. Pearce RE, Leeder JS, Kearns GL: Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos 2006;34:1035-1040

2. Paton J, Jardine E, McNeill E, et al: Adrenal responses to low dose synthetic ACTH (Synacthen) in children receiving high dose inhaled fluticasone. Arch Dis Child 2006;91:808-813

3. Callejas SL, Biddlecombe RA, Jones AE, et al: Determination of the glucocorticoid fluticasone propionate in plasma by automated solid-phase extraction and liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 1998;718:243-250

4. Bender BG, Bartlett SJ, Rand CS, et al: Impact of interview mode on accuracy of child and parent report of adherence with asthma-controller medication. Pediatrics. 2007;120:e471-477

5. National Asthma Education and Prevention Program: Expert Panel Report 3 (EPR-3):Guidelines for the Diagnosis and Management of Asthma -Summary Report 2007. J Allergy Clin Immunol. 2007 Nov;120(5 Suppl):S94-138